---
title: "LIVZON GROUP: The company's semaglutide injection for weight loss indications has completed patient enrollment in Phase III clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/259235513.md"
description: "On September 29th, LIVZON GROUP stated on the interactive platform that the Phase III clinical trial for the weight loss indication of its semaglutide injection has completed enrollment. The trial is designed as a head-to-head comparison with the original product, and the clinical follow-up is progressing smoothly. The company will continue to promote project progress with a scientifically efficient research and development strategy, and relevant research results and subsequent application plans will be disclosed in a timely manner in accordance with regulatory requirements"
datetime: "2025-09-29T01:02:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/259235513.md)
  - [en](https://longbridge.com/en/news/259235513.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/259235513.md)
generator: "portal-rs"
---

# LIVZON GROUP: The company's semaglutide injection for weight loss indications has completed patient enrollment in Phase III clinical trials

On September 29th, LIVZON GROUP stated on the interactive platform that the Phase III clinical trial for the weight loss indication of its Semaglutide injection has completed enrollment. The trial is designed as a head-to-head comparison with the original product, and the clinical follow-up is progressing smoothly. The company will continue to promote project progress with a scientifically efficient research and development strategy, and relevant research results and subsequent application plans will be disclosed in a timely manner in accordance with regulatory requirements

### Related Stocks

- [000513.CN](https://longbridge.com/en/quote/000513.CN.md)
- [01513.HK](https://longbridge.com/en/quote/01513.HK.md)

## Related News & Research

- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [Tai Hing Group Holdings (SEHK:6811) Stock Price Tracks Profit Rebound Against Thin Margins](https://longbridge.com/en/news/296688951.md)
- [Labubu maker Pop Mart set for drastic growth slowdown as bears gather](https://longbridge.com/en/news/296428956.md)
- [POP MART's Twinkle Twinkle Farm Tales Series Sells Out Instantly at Launch; Hidden Edition Resold at ~14x Premium](https://longbridge.com/en/news/296560057.md)
- [SMOORE INTL  1H26 Net Profit Up 16.2% YoY to RMB572M; Interim DPS Maintained at HKD0.2](https://longbridge.com/en/news/296421803.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**